氯氮平联合利培酮治疗伴攻击行为精神分裂症患者对照研究

目的探讨氯氮平联合利培酮治疗伴攻击行为精神分裂症患者的临床疗效及安全性。方法将72例伴攻击行为的精神分裂症患者随机分为两组各36例，两组均给予氯氮平治疗，研究组在此基础上联合利培酮治疗。疗程均为6w。于治疗前和治疗1w、2w、4w、6w末采用简明精神病量表和攻击行为观察量表评定临床疗效。结果治疗1w末起，两组简明精神病量表总分、研究组攻击行为量表评分均较治疗前有极显著下降（P〈0．01）；治疗2w末起对照组攻击行为量表评分较治疗前有极显著下降（P〈0．01）。两组间同期评分比较研究组较对照组下降更显著（P〈0．05或0．01）；两组不良反应相当（P〉0．05），且均较轻微。结论氯氮平联合利培酮治疗伴攻击行为精神分裂症患者起效快，疗效更显著，不良反应率和程度并不增加，值得临床推广应用。

A control study on risperdone combined with clozapine in the treatment of schizophrenia with aggressive behavior

Objective To explore the curative effect and safety of risperdone combined with clozapine in the treatment of schizophrenia with aggressive behavior.Methods 72 schizophrenics with aggressive behavior were randomly divided into research group(n=two groups.The patients(n=36)in group A were treated with risperdone combined with clozapine,with the control of group B(n=36)only with clozapine,both for six weeks.The Scales of Brief Psychiatric Rating Scale(BPRS)and Attack Behavior Observation Scale(ABOS)were evaluated before and after 1,2,4,6 weeks of treatment.Results Two groups showed fine efficacy,but group A effected faster one week than group B(P<0.01).Besides,at different time points the BPRS scores and the ABOS scores in group A were lower than those in group B with statistically significant difference(P<0.05 or P<0.01).There was no significant difference in side effects between the two groups(P>0.05).Conclusion Risperdone combined with clozapine was more effective than clozapine alone in the treatment of schizophrenia with attack behavior.